Qureight AI to Power Calluna’s Phase 2 IPF Study
AI-powered 3D lung imaging to accelerate assessment of CAL101, a first-in-class antibody targeting a key driver of fibrosis.
Qureight, a leading techbio company transforming clinical imaging through AI, today announced it will provide its advanced 3D imaging platform to support Calluna Pharma’s Phase 2 AURORA trial of CAL101, a novel investigational therapy for idiopathic pulmonary fibrosis (IPF).
The partnership brings together cutting-edge imaging analytics and innovative drug development to tackle one of the most challenging and life-limiting lung diseases. IPF is a progressive and currently incurable condition with limited treatment options. CAL101, Calluna’s lead monoclonal antibody, targets S100A4, a protein that acts as an upstream amplifier of multiple pro-fibrotic pathways involved in IPF.
Qureight’s platform will be used throughout the trial to deliver high-resolution, quantitative assessments of lung anatomy, including fibrosis volume and other imaging biomarkers. These insights will inform both patient selection and ongoing efficacy evaluation.
“Calluna’s decision to work with us on this pivotal trial reflects the power of our AI platform to deliver real-time, clinically meaningful data,” said Steven Bishop, Chief Data Officer at Qureight. “IPF is a disease where time matters, for both patients and drug developers. Our technology enables faster, more precise evaluation of how new therapies impact lung structure, helping accelerate progress in this high-need area.”
The AURORA study is a randomised, double-blind, placebo-controlled trial enrolling 150 IPF patients across more than 50 global sites in the US, UK, EU, Turkey, and South Korea. Participants will receive seven monthly infusions of CAL101 or placebo, with forced vital capacity (FVC), a key measure of lung function, serving as the primary endpoint.
Qureight’s AI tools will allow researchers to detect subtle changes in lung fibrosis that are often missed by conventional image interpretation. Unlike traditional methods, which are manual, slow, and susceptible to human variability, Qureight’s platform delivers standardised, high-fidelity results that can be acted on quickly.
“Dosing the first patient in AURORA marked a major milestone for Calluna and our mission to transform outcomes for people living with IPF,” said Dr. Jonas Hallén, Co-Founder and Chief Medical Officer at Calluna Pharma. “Qureight’s imaging technology is an integral part of the study, giving us critical, data-driven insight into how CAL101 may halt or slow lung function decline.”
The collaboration underscores a growing trend in clinical research: integrating AI and digital health tools to de-risk development and accelerate timelines. Qureight’s role in AURORA highlights how advanced imaging analytics can enhance both the scientific rigor and efficiency of trials in complex diseases like IPF.
About Qureight
Qureight is a Cambridge-based techbio company using AI and cloud-based platforms to curate, analyze, and interpret imaging and clinical data in complex lung and heart diseases. Its technology enables real-time insights to support faster, more accurate clinical decision-making and drug development.
About Calluna Pharma
Calluna Pharma is a clinical-stage biopharmaceutical company developing novel therapies for fibrotic and inflammatory diseases. Its lead candidate, CAL101, is a first-in-class monoclonal antibody targeting S100A4, a key molecular driver of fibrosis.
Author
BioFocus Newsroom